首页 / 院系成果 / 成果详情页

Short-term intratracheal use of PEG-modified IL-2 and glucocorticoid persistently alleviates asthma in a mouse model 期刊论文

编号：

a9f2944e-cdef-421e-ae7f-0db046ae7a23
作者：

Wu, Kefei^[1];Ma, Jiexian^[1];Bai, Weiya^[2,3];Cui, Xiaoxian(崔晓娴)^[2,3]Han, Tao^[1];Wang, Shiyuan^[4];Xie, Youhua(谢幼华)*^[2,3]Xie, Yanhui(谢彦晖)^[1]
语种：

English
期刊：

SCIENTIFIC REPORTS ISSN：2045-2322 2016 年 6 卷 ; AUG 16
收录：
摘要：

Regulatory T (Treg) cells play an important role in allergic airway diseases, and upregulation of Treg cells is a potential therapeutic strategy for asthma. In this study, we show that short-term intratracheal use of IL-2 combined with glucocorticoid alleviates antigen-induced airway inflammation and reduces airway hyperresponsiveness by expanding antigen-nonspecific Treg cells, with a decrease in T helper 2 (Th2) cells and Th2-associated cytokines. We also designed a long-acting polyethylene glycol (PEG)modified IL-2 and demonstrated that the optimal dosage form is IL-2(PEG) plus budesonide, which can upregulate Treg cells and ameliorate asthma at a lower dose. The therapeutic effect was faster than treatment with dexamethasone and was effective at a low dose suitable for humans that could last for at least 6 weeks. This study unveils a new therapeutic regimen and suggests that such endogenous Treg therapy could be a useful tool to persistently alleviate asthma.
推荐引用方式
GB/T 7714：

Wu Kefei,Ma Jiexian,Bai Weiya, et al. Short-term intratracheal use of PEG-modified IL-2 and glucocorticoid persistently alleviates asthma in a mouse model [J].SCIENTIFIC REPORTS,2016,6.
APA：

Wu Kefei,Ma Jiexian,Bai Weiya,Cui Xiaoxian,&Xie Yanhui.(2016).Short-term intratracheal use of PEG-modified IL-2 and glucocorticoid persistently alleviates asthma in a mouse model .SCIENTIFIC REPORTS,6.
MLA：

Wu Kefei, et al. "Short-term intratracheal use of PEG-modified IL-2 and glucocorticoid persistently alleviates asthma in a mouse model" .SCIENTIFIC REPORTS 6(2016).

浏览次数：5  下载次数：0

分享到：

浏览次数：5

下载次数：0

打印次数：0